Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis

被引:9
|
作者
Beaver, Thomas [1 ]
Bavaria, Joseph E. [2 ]
Griffith, Bartley [3 ]
Svensson, Lars G. [4 ]
Pibarot, Philippe [5 ]
Borger, Michael A. [5 ]
Sharaf, Omar M. [1 ]
Heimansohn, David A. [6 ]
Thourani, Vinod H. [7 ]
Blackstone, Eugene H.
Puskas, John D. [8 ]
机构
[1] Univ Florida Hlth, Div Cardiovasc Surg, Gainesville, FL USA
[2] Hosp Univ Penn, Dept Cardiovasc Surg, Philadelphia, PA USA
[3] Univ Maryland, Med Ctr, Dept Surg, Baltimore, MD USA
[4] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Cleveland, OH USA
[5] Laval Univ, Quebec Heart & Lung Inst, Dept Cardiol, Quebec City, PQ, Canada
[6] St Vincent Heart Ctr Indiana, Indianapolis, IN USA
[7] Piedmont Heart Inst, Marcus Valve Ctr, Dept Cardiovasc Surg, Atlanta, GA USA
[8] Mt Sinai Morningside, Dept Cardiovasc Surg, New York, NY USA
来源
关键词
aortic valve replacement; aortic valve disease; bioprosthetic valve; RESILIA tissue; PRESERVATION TECHNOLOGY; DEFINITIONS; GUIDELINES; DABIGATRAN; WARFARIN; FAILURE;
D O I
10.1016/j.jtcvs.2023.09.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: As bioprosthetic aortic valve replacement (AVR) extends to younger cohorts, tissue durability is of paramount importance. We report 7-year outcomes from an AVR bioprosthesis utilizing novel tissue. Methods: This was an international investigational device exemption trial for novel AVR with annual follow-up and a subset re-consented at 5 years for extended 10-year follow-up. Safety end points and echocardiographic measurements were adjudicated by an independent clinical events committee and by a dedicated core laboratory, respectively. Results: Between January 2013 and March 2016, 689 patients underwent AVR with the study valve. Mean age was 66.9 +/- 11.6 years, Society of Thoracic Surgeons risk score was 2.0% % +/- 1.8%, % , and 74.3% % of patients were New York Heart Association functional class II and III. Five-year follow-up was completed by 512 patients, and 225 re-consented for extended follow-up. Follow-up duration was 5.3 +/- 2.2 years (3665.6 patient-years), and 194 and 195 patients completed 6-and 7-year follow-ups, respectively. One-, 5-, and 7-year freedom from all-cause mortality was 97.7%, % , 89.4%, % , and 85.4%, % , respectively. Freedom from structural valve deterioration at 7 years was 99.3%. % . At 7 years, effective orifice fi ce area and mean gradients were 1.82 +/- 0.57 cm(2) (n = 153), and 9.4 +/- 4.5 mm Hg (n = 157), respectively. At 7 years, predominantly none (96.8% % [152 out of 157]) or trivial/trace (2.5% % [4 out of 157]) paravalvular regurgitation and none (84.7% % [133 out of 157]) or trivial/trace (11.5% % [18 out of 157]) transvalvular regurgitation were observed. Conclusions: We report the longest surgical AVR follow-up with novel tissue in an investigational device exemption trial utilizing an independent clinical events committee and an echocardiography core laboratory. This tissue demonstrates excellent outcomes through 7 years and is the benchmark for future surgical and transcatheter prostheses.
引用
收藏
页码:781 / 791
页数:11
相关论文
共 50 条
  • [41] Percutaneous aortic valve replacement with the CoreValve bioprosthesis - Reply
    Marcheix, Bertrand
    Cartier, Raymond
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (06): : 1408 - 1408
  • [42] eComment. Choice of bioprosthesis for aortic valve replacement
    Dimitrakakis, Georgios
    von Oppell, Ulrich O.
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2013, 16 (03) : 374 - 374
  • [43] Up to Seven-Year Outcomes After Transcatheter Pulmonary Valve Replacement in the Prospective Multicenter US Melody Valve Investigational Device Exemption Trial
    Cheatham, John P.
    Vincent, Julie A.
    Zahn, Evan M.
    Bergersen, Lisa
    Berman, Darren P.
    Lock, James E.
    Hellenbrand, William E.
    Jones, Thomas K.
    McElhinney, Doff B.
    CIRCULATION, 2014, 130
  • [44] Sutureless aortic valve replacement in stentless bioprosthesis failure
    Kim, Jae Hyun
    Kim, Jae-Bum
    Choi, Sae Young
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2015, 21 (06) : 801 - 802
  • [45] Mid-term outcomes of the COMMENCE trial investigating mitral valve replacement using a bioprosthesis with a novel tissue
    Heimansohn, David A.
    Baker, Craig
    Rodriguez, Evelio
    Takayama, Hiroo
    Dagenais, Francois
    Talton, David S.
    Mumtaz, Mubashir A.
    Pibarot, Philippe
    Puskas, John D.
    JTCVS OPEN, 2023, 15 : 151 - +
  • [46] Outcomes following transcatheter aortic valve replacement in patients with native aortic valve regurgitation
    Bob-Manuel, Tamunoinemi
    Kadire, Siri
    Heckle, Mark R.
    Wang, Jiajing
    Ibebuogu, Uzoma N.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (01)
  • [47] ONE YEAR OUTCOMES FOLLOWING BIOPROSTHETIC VALVE FRACTURE TO FACILITATE VALVE-INVALVE TRANSCATHETER AORTIC VALVE REPLACEMENT
    Chhatriwalla, Adnan
    Allen, Keith B.
    Saxon, John
    Webb, John
    Whisenant, Brian
    Yakubov, Steven J.
    Harvey, James
    Stegman, Brian Matthew
    Tseng, Elaine
    Gerdisch, Marc
    Garrett, H. Edward
    Sanchez, Carlos E.
    Williams, Paul
    Sathananthan, Janarthanan
    Alhawasli, Hazem
    Kennedy, Kevin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1106 - 1106
  • [48] Percutaneous aortic valve replacement for severe aortic stenosis by CoreValve bioprosthesis
    Schuler, G.
    Linke, A.
    Moebius-Winkler, S.
    Mohr, F.
    Walther, T.
    Fassl, J.
    CIRCULATION, 2008, 118 (12) : E428 - E429
  • [49] 1-Year Outcomes following Bioprosthetic Valve Fracture to Facilitate Valve-in-Valve Transcatheter Aortic Valve Replacement
    Chhatriwalla, Adnan K.
    Allen, Keith B.
    Saxon, John T.
    Cohen, David J.
    Nguyen, Tom C.
    Loyalka, Pranav
    Whisenant, Brian
    Yakubov, Steven J.
    Sanchez, Carlos
    Sathananthan, Janarthanan
    Stegman, Brian
    Harvey, James
    Garrett, H. Edward
    Tseng, Elaine
    Gerdisch, Marc
    Williams, Paul
    Kennedy, Kevin F.
    Webb, John
    STRUCTURAL HEART-THE JOURNAL OF THE HEART TEAM, 2021, 5 (03): : 312 - 318
  • [50] Five-year Outcomes of the COMMENCE Trial Investigating Aortic Valve Replacement With RESILIA Tissue
    Bavaria, Joseph E.
    Griffith, Bartley
    Heimansohn, David A.
    Rozanski, Jacek
    Johnston, Douglas R.
    Bartus, Krzysztof
    Girardi, Leonard N.
    Beaver, Thomas
    Takayama, Hiroo
    Mumtaz, Mubashir A.
    Rosengart, Todd K.
    Starnes, Vaughn
    Timek, Tomasz A.
    Boateng, Percy
    Ryan, William
    Cornwell, Lorraine D.
    Blackstone, Eugene H.
    Borger, Michael A.
    Pibarot, Philippe
    Thourani, Vinod H.
    Svensson, Lars G.
    Puskas, John D.
    ANNALS OF THORACIC SURGERY, 2023, 115 (06):